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of arrhythmiahas has statistical signiﬁcance, OR¼3.39, 95% CI 2.30-5.00, which
means that the clinical total effective rate of the treatment of arrhythmia mainly using
Wendan decoction was superior to the control group; in the comparison with control
group, the symptoms improved efﬁciency of the Wendan decoction in the treatment of
arrhythmiahas has statistical signiﬁcance, OR¼2.65, 95% CI 1.24-5.67, which means
that the symptoms improved efﬁciency of the treatment of arrhythmia mainly using
Wendan decoction was superior to the control group; in the comparison with control
group, the electrocardiogram improved efﬁciency of the Wendan decoction in the
treatment of arrhythmiahas also has statistical signiﬁcance, OR¼2.65, 95% CI 1.24-
5.67, which means that the electrocardiogram improved efﬁciency of the treatment of
arrhythmia mainly using Wendan decoction was superior to the control group. The
funnel plot point out that there may be publication bias. The results of sensitivity
analysis are the same as the original. The results analyzed by Meta-analysis were
stable and reliable.
Conclusions: Wendan decoction is effective to treat arrhythmia,improve the
clinical symptoms and electrocardiogram of arrhythmia. But because the quality
and quantity of the research are limited, further conﬁrmation with clinical ran-
domized controlled trials of high quality, large sample and long-term follow-up are
needed.
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Objectives: To investigate the acute effects of inhaled iloprost on V/Q matching, and
hemodynamics in patients with pulmonary hypertension (PH) due to chronic lung
diseases.
Methods: Sixty-nine patients with chronic lung diseases and PH were diagnosed by
right heart catheterization (RHC).All patients received a single dose of 20mg iloprost
during the process of RHC, Cardiopulmonary data included hemodynamic parameters
and PaO2, PaCO2, SaO2, P(A-a) O2, venous admixture/shunt fraction (Qs$/Qt) were
measured or calculated at baseline, and 20 minutes after inhalation iloprost
respectively.
Results: nhalated iloprost caused a decrease in mPAP from 44.510.5mmHg to
41.611.4mmHg, and PVR from 7.63.6 Wood Units to 6.63.9 Wood Units
(meanSD, P<0.001, respectively), cardiac index increase from 3.20.8 L/min/m2 to
3.51.0L/min/m2 (meanSD, P<0.001). Arterial blood gas and calculated Qs$/Qt$
were maintained after iloprost. No adverse effects on systemic blood pressure were
seen.
Conclusions: Iloprost inhalation was safe in patients with PH due to lung diseases,
and improved hemodynamics but didn’t affect V/Q matching and gas change.
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Objectives: To compare the change of cardiac output(CO) during loading dose were
injecting between dexmedetomidine and propofol in patients after major abdominal
surgery.
Methods: 74 patients after major abdominal surgery were enrolled. They were
randomly divided into two groups: Dexmedetomidine group (DEX group) or Propofol
group (PRO group), 37 cases in each group. Depth of sedation was monitored using
the bispectral index (BIS), CO and other cardiodynamic date were recorded through
“Vigileo” and cardiogram monitor. When the patients could be roused, a loading
dose of fentanyl was injected at 0.0007mg/kg, followed by continuous infusion at
0.3mg/kg/h for additional analgesia. DEX group received 1 mg/kg loading dose fol-
lowed by continuous infusion of 0.3mg/kg/h. PRO group received 0.5mg/kg loading
dose followed by continuous infusion at 0.5mg/kg/h. Dose were adjusted to accom-
plish BIS value 70-80. BIS value, HR (Heart rate), SV (stroke volume) and CO were
recorded at 0min, 5min, 10min, 30min.
Results: Both groups were able to achieve the target sedation level according to BIS
value. There were no differences in BIS values between DEX group and PRO group
(61.2312.73 vs 62.5513.67 P¼0.127). After the loading dose, DEX group caused
HR decrease signiﬁcantly than PRO group [P¼0.006]. SV showed different effect in
both groups, SV augmented signiﬁcantly in DEX group after the loading dose, as SV
decreased signiﬁcantly in PRO group. SV were signiﬁcantly decreased in PRO groups
than DEX groups (6423 vs 9029ml, P¼0.008) in the ﬁfth minutes. HR decreased
signiﬁcantly in DEX group during the loading dose period, HR decreased slightly in
PRO group, HR were signiﬁcant different between the two groups (7214 vs
8415bpm, P¼0.006). CO declined signiﬁcantly in groups comparing to the level
before the sedation (PDex<0.001, PPro<0.001). CO were signiﬁcantly decreased in
PRO groups than DEX groups in the ﬁfth minutes (5.41.7 vs 6.42.0 L/min,
P<0.05).JACC Vol 64/16/Suppl C j October 16–19, 2014 j GW-ICC Abstracts/CConclusions: Propofol can signiﬁcant decrease cardiac output than dexmedetomidine
during the loading time in the patients after major abdominal surgery. So monitoring
the cardiodynamics changes carefully during sedation are required.
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Objectives: Comparison of the inﬂuence on the platelet aggregation of clopidogrel
combined with different metabolic pathways statins in patients with acute myocardial
infarction.
Methods: From May 2013 to November 2013, there were 80 patients with acute
myocardial infarction treated with emergency PCI enrolled into this study. They were
randomly divided into the atorvastatin group (group A 40 cases); rosuvastatin group
(group B 40 cases). All patients chewed Aspirin 300mg and received clopidogrel
300mg before emergency PCI. Patients in group A received atorvastatin 80mg, Group
B received rosuvastatin 40mg before emergency PCI. Patients in group A received
atorvastatin 40mg/qd and patients in group B received rosuvastatin 20mg/qd after PCI.
All patients received dual antiplatelet therapy with aspirin 100mg/qd and clopidogrel
75mg/qd.Statins and clopidogrel were given before breakfast. The platelet aggregation
rate was measured with whole blood impedance aggregometry on the 7 days and 30
days. We observed the major adverse cardiovascular events (MACE): cardiac death,
recurrent angina, recurrent myocardial infarction, target vessel revascularization and
deterioration of cardiac function in patients after 30 days. We compared the difference
of platelet aggregation and MACE rate between the two groups. Testing the alanine
aminotransferase, creatinine, total cholesterol and low-density lipoprotein in the ﬁrst
24 hours and 30 days after PCI and recording the quantity of patients who had muscle
pain , headache, and so on after 30 days to evaluate the effects of lipid-lowering and
drug safety.
Results: (1).After PCI, on the 7th day and 30th day, we compared the platelet ag-
gregation of group A with group B. The result were (3.093.99 vs 3.794.20
P¼0.45) and (2.593.48 vs 2.994.20 P¼0.6). The platelet aggregation of group B
was slightly higher than group A in the both time but no statistical difference. (2) After
30 days, there were 9 patients (22.5%) with recurrent angina, 3 patients (7.5%) with
deterioration of heart function in group A and 5 patients (12.5%) with recurrent
angina, 4 patients (10 %) with deterioration of heart function in group B. There was no
signiﬁcant difference between the two groups of patients in adverse events and overall
MACE (P> 0.05). (3) After 30 days the level of patients’ TC and LDL-C was
decreased signiﬁcantly (P<0.05). According to the level of LDL-C <1.8mmol / l or
LDL-C decreased by 50% compared to the admission, we compared the percentage of
patients who’s level of LDL-C reached the goal in the two groups (55% vs 62.5%
P¼0.49). (4) The level of patients’ ALT and Cr were no signiﬁcant difference
compared to the admission (P>0.05). There was one patients (2.5%) with
ALT>3ULN in group A and 0 in group B. There was no patient with CK>5ULN.
Conclusions: The effect of different dose of statins on the antiplatelet potency of
clopidogrel inpatients with acute myocardial infarction was similar.
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Objectives: Nesiritide is prescribed to the patients with acute decompensate heart
failure (ADHF) with dyspnea according to 2012 European Society of Cardiology
(ESC) guidelines. However, a few randomized, controlled trials (RCTs) were carried
out in recent years and there has been conﬂicting reports on the effects of Nesiritide to
improve the rate of mortality and rehospitalization. Therefore, we conducted a meta-
analysis with the addition of new RCTs to produce a more reliable conclusion about
the beneﬁts received from the short- and long-term Nesiritide therapy in adults with
ADHF. Additionally, a cumulative meta-analysis on how evidence for Nesiritide has
evolved in the treatment of ADHF was performed.
Methods: To identify RCTs that evaluated the mortality and adverse events on adults
with ADHF after Nesiritide therapy, extensive searches were carried out within
MEDLINE, EMBASE, CINAHL, SIGLE, Web of Science and the Cochrane Central
Register of Controlled Trials (through August 10, 2013). When necessary, searches of
bibliographies using Medical Subject Heading terms and a standardized protocol were
also performed. Two independent reviewers identiﬁed trials, extracted data, and
assessed risk of bias.
Results: A total of 10213 patients with ADHF in ﬁfteen trials were included and
divided into the Nesiritide group (Nesiritide plus conventional treatment) and theardiovascular Disease Clinical Research C205
